ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.667
-0.20%
Brent Oil
81.965
0.00%
Bitcoin
68,871.35
-0.57%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Clarus Therapeutics Holdings Inc (CRXT)

  7. Clarus Therapeutics Holdings Inc (CRXT) Noticias

CRXT

Clarus Therapeutics (CRXT)

Clarus Therapeutics Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CRXT
FechaHoraFuenteTítuloSímboloCompañía
07/03/202305:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CRXTClarus Therapeutics Holdings Inc
01/03/202306:36Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CRXTClarus Therapeutics Holdings Inc
01/03/202306:23Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CRXTClarus Therapeutics Holdings Inc
01/03/202306:20Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CRXTClarus Therapeutics Holdings Inc
22/02/202315:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CRXTClarus Therapeutics Holdings Inc
18/10/202215:05GlobeNewswire Inc.Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful BidderNASDAQ:CRXTClarus Therapeutics Holdings Inc
14/09/202208:52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CRXTClarus Therapeutics Holdings Inc
05/09/202221:19GlobeNewswire Inc.Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeNASDAQ:CRXTClarus Therapeutics Holdings Inc
26/08/202215:37Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:CRXTClarus Therapeutics Holdings Inc
22/08/202211:05TipRanksClarus Therapeutics Holdings (CRXT) was downgraded to a Hold Rating at NeedhamNASDAQ:CRXTClarus Therapeutics Holdings Inc
19/08/202205:13Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CRXTClarus Therapeutics Holdings Inc
18/08/202215:05GlobeNewswire Inc.Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce ReductionNASDAQ:CRXTClarus Therapeutics Holdings Inc
28/07/202208:05GlobeNewswire Inc.Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)NASDAQ:CRXTClarus Therapeutics Holdings Inc
06/07/202215:00Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CRXTClarus Therapeutics Holdings Inc
09/06/202208:05GlobeNewswire Inc.Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual MeetingNASDAQ:CRXTClarus Therapeutics Holdings Inc
24/05/202216:28Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:CRXTClarus Therapeutics Holdings Inc
18/05/202208:05GlobeNewswire Inc.Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)NASDAQ:CRXTClarus Therapeutics Holdings Inc
17/05/202205:16TipRanksNeedham Thinks Clarus Therapeutics Holdings’ Stock is Going to RecoverNASDAQ:CRXTClarus Therapeutics Holdings Inc
16/05/202215:05GlobeNewswire Inc.Clarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsNASDAQ:CRXTClarus Therapeutics Holdings Inc
12/05/202208:05GlobeNewswire Inc.Clarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsNASDAQ:CRXTClarus Therapeutics Holdings Inc
10/05/202208:05GlobeNewswire Inc.Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisNASDAQ:CRXTClarus Therapeutics Holdings Inc
09/05/202215:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CRXTClarus Therapeutics Holdings Inc
09/05/202208:05GlobeNewswire Inc.Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual MeetingNASDAQ:CRXTClarus Therapeutics Holdings Inc
28/04/202208:05GlobeNewswire Inc.Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)NASDAQ:CRXTClarus Therapeutics Holdings Inc
27/04/202215:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CRXTClarus Therapeutics Holdings Inc
27/04/202212:43GlobeNewswire Inc.Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public OfferingNASDAQ:CRXTClarus Therapeutics Holdings Inc
27/04/202205:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:CRXTClarus Therapeutics Holdings Inc
25/04/202208:20GlobeNewswire Inc.Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public OfferingNASDAQ:CRXTClarus Therapeutics Holdings Inc
25/04/202205:52Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:CRXTClarus Therapeutics Holdings Inc
22/04/202205:15Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CRXTClarus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:CRXT

Su Consulta Reciente

LSE
TABS
Tabs Cdx (usd)
BIT
F17208
Vontobel Financial Produ...
NASDAQ
DSP
Viant Technology
LSE
57CC
Assa 3.205%
LSE
10SP
Nationwde.25
AQSE
AFRN.GB
Aferian
NYSE
FPT
USOTC
OSAGF
Osram Licht AG Namens (CE)
COIN
NFTIETH
NFT INDEX
ASX
PMVKOQ
LSE
ZY12
Citi Fun 25
NASDAQ
AIH
Aesthetic Medical
BITMOT
929689
Eib Tf 1,75% Mz29 Usd
BOV
ENJU3M
Enjoei ON
EU
B678T
B678T
BIT
UC6M2Q
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados